 |
Introduction
The 14th Congress of the European Hematology Association (EHA) was held June 4-7, 2009 in Berlin, Germany. With over 2,000 abstracts submitted, this congress endeavored to promote not only excellence in clinical practice and research, but also in hematology education. This newsletter summarizes the following areas of hematologic malignancies as presented by experts in their respective fields.
Featured Content
• Chronic Lymphocytic Leukemia
• Follicular Lymphoma
• Diffuse Large B-Cell Lymphoma
• Multiple Myeloma
• Chronic Myelogenous Leukemia
• Acute Myelogenous Leukemia
Editors
Harry P. Erba, MD, PhD, bio | Robert E. Marcus, MA, FRCP, FRCPath, bio
Media: Newsletter
Estimated time to complete activity: 1.5 hours. Release date: July 28, 2009 | Expiration date: July 27, 2010
Statement of Need
Inclusive of lymphoma, multiple myeloma, and leukemia, an estimated 140,000 new hematologic malignancy cases are expected to be diagnosed in the United States in 2009. Even with treatment advancements for these hematologic malignancies, approximately 53,000 individuals will die secondary to their malignancy. The treatment of hematologic malignancies remains a challenge for many healthcare professionals and patients despite recent gains made in the management of these diseases. Determining which treatment approach is most appropriate for a given patient requires careful consideration of patient-specific characteristics, physician expertise, and available health-system resources. While difficult, these decisions require knowledge of current clinical and experimental data in order for the appropriate utilization of therapeutic agents and strategies in clinical practice. This educational program provides participants with an overview of the most recent advances in the treatment of hematologic malignancies, as well as specific updates and outcomes of ongoing clinical trials, synthesized into a concise learning opportunity by experts in the field. The cutting-edge data these experts will present will provide practitioners with the information they need to incorporate new therapeutic strategies into their patient care decisions. As a result, it will lead to improved response and survival rates for patients with hematologic malignancies while minimizing adverse events and maintaining or improving patient quality of life.
Target Audience
The target audience for the program includes hematologists, medical oncologists, hematologist-oncologists, oncology specialty pharmacists, and oncology nurses charged with the care of patients with hematologic malignancies.
Learning Objectives
Upon completion of this educational program, participants should be better able to:
- Describe the potential role of novel treatment strategies in the management of hematologic malignancies
- Compare available treatment options for patients with hematologic malignancies in respect to efficacy and toxicity parameters
- Describe the proposed mechanism of action of new and emerging therapeutic agents utilized to improve remission and survival rates for patients with hematologic malignances
- Discuss implications of updated safety and efficacy data for clinically available treatment options for patients with hematologic malignancies
_____________________________________________________________________________________________________________________________________ |
ACCREDITATION INFORMATION
PHYSICIAN CONTINUING EDUCATION
ACCREDITATION STATEMENT
Educational Concepts Group, LLC is accredited by the Accreditation Council
for Continuing Medical Education to provide continuing medical education
for physicians.
CREDIT DESIGNATION STATEMENT
Educational Concepts Group, LLC designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim
credit commensurate with the extent of their participation in the activity.
PHARMACIST CONTINUING EDUCATION
|
 |
| Educational Concepts Group, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. |
|
Type of Activity: Knowledge-based
Educational Concepts Group, LLC designates this continuing education activity for 1.5 contact hours (0.15 CEUs) (UPN 199-000-09-030-H01-P).
|
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME/CE credit for this activity. During the period July 28, 2009 through July 27, 2010, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the post-test and activity evaluation form.
CME/CE CREDIT
Physicians and pharmacists who complete the post-test with a score of 70% or better may view and print their credit letter or statement of credit via the website, www.educationalconcepts.net.
DISCLOSURE OF OFF-LABEL USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Educational Concepts Group, LLC (ECG) does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity do not necessarily represent the views of ECG. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
CME/CE INQUIRIES
For further information, please contact
Educational Concepts Group, LLC
1300 Parkwood Circle SE | Suite 325
Atlanta, Georgia 30339
Phone: 1.770.933.1681 | Fax: 1.770.933.1692
www.educationalconcepts.net
None of the contents may be reproduced in any form without prior written permission from the publisher. This activity may be accessed at www.educationalconcepts.net. |
|
FACULTY DISCLOSURE STATEMENT
All faculty participating in continuing education activities sponsored by ECG are expected to disclose to the audience any real or apparent commercial financial affiliations related to the content of their presentations/materials.
THE FOLLOWING FACULTY MEMBERS HAVE DECLARED RELEVANT FINANCIAL RELATIONSHIPS
Harry P. Erba, MD, PhD
Speakers’ Bureau
Bristol-Myers Squibb Company, Celgene Corporation, Cephalon, Eisai Inc., Novartis, Pharmion
Grants/Research Support
Cell Therapeutics, Cephalon, Eli Lilly and Company, Genzyme Corporation, Kanisa, Novartis, Wyeth Pharmaceuticals, Xanthus
Consultant Fees
Genzyme Corporation
Robert E. Marcus, MA, FRCP, FRCPath
Consultant Fees, Honorarium, Speakers’ Bureau
Mundipharma, Roche
ECG HAS DECLARED THE FOLLOWING FINANCIAL RELATIONSHIPS
ECG receives educational grants from pharmaceutical industry and other commercial sources. Planners, managers, and other staff members at ECG have no relevant financial relationships to disclose.
ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT
This activity is supported by educational grants from Celgene Corporation and
Merck & Co., Inc.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Please refer to the official prescribing information for each product or consult the Physicians’ Desk Reference for discussion of approved indications, contraindications, and warnings.
|
|
|
